🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FGF21 has become a focus of intense interest in biotechnology.Learn more about our catalog:en.genomeditech.com/search?kwd=FGF…

IL-5:ATS 2025 Update: GSK Builds Momentum for Depemokimab.Learn more about our catalog: en.genomeditech.com/cell-line/Cyto…

BCMA: CHMP Recommends GSK’s Blenrep for Multiple Myeloma. Learn more about our catalog: en.genomeditech.com/cell-line/TAA/…

EGFR: Clinical Update: Promising Results for Petosemtamab + Pembrolizumab in 1L PD-L1+ r/m HNSCC.Learn more about our EGFR catalog: en.genomeditech.com/cell-line/Kina…

Eli Lilly and Camurus Join Forces to Advance Long-Acting Obesity Treatments.Learn more about our catalog: en.genomeditech.com/cell-line/GPCR…

Tarlatamab Sets a New Standard in SCLC Second-Line Treatment.Learn more about our catalog: en.genomeditech.com/cell-line/TAA/…

HER2：T-DXd Plus Pertuzumab Shows Superior PFS in HER2-Positive Breast Cancer.Learn more about our catalog: en.genomeditech.com/cell-line/Kina…

BCMA：Cullinan Strikes $700M Deal for BCMA Bispecific Velinotamig.Learn more about our catalog: en.genomeditech.com/cell-line/TAA/…

CD19/CD20：J&J's Dual-Targeting CAR-T Shows 100% Response Rate in EarlyLymphoma Trial.Learn more about our catalog: en.genomeditech.com/cell-line/TAA/…

【In Vivo Grade】Mouse-Derived Anti-Mouse Antibodies .Explore how our antibodies can accelerate your research: en.genomeditech.com/antibody/In-Vi…

At Genomeditech, our Protein Expression Platform empowers scientists with 160+ high-quality recombinant proteins.Get in touch to learn how we can support your next breakthrough.en.genomeditech.com/protein

See you tomorrow at CBA-China 2025!Genomeditech is excited to join the Chinese Biopharmaceutical Association Annual Conference on June 27–28 at the Suzhou International Expo Center.Visit us at Booth DT34 ！

Discover Genomeditech’s Complete ActRII Target Series for Muscle and Metabolic Research.Get in touch to learn how we can support your next breakthrough.en.genomeditech.com/cell-line/Cyto…

July is Sarcoma Awareness Month — a time to spotlight one of the most challenging and under-recognized groups of cancers.Let’s continue to raise awareness, advance research, and amplify the voices of those affected.en.genomeditech.com

CD3 TCEs are making headlines again.Amid the growing buzz around bispecific and trispecific antibody development, new partnerships and evolving applications are rapidly reshaping the immunotherapy landscape.Learn more about our catalog: en.genomeditech.com/cell-line/Immu…

Reliable CD3 Cell Lines for T-Cell Research & Bispecific Antibody Evaluation.Learn more about our catalog: en.genomeditech.com/cell-line/Immu…

CD276 is rapidly emerging as a critical focus in next-generation antibody-drug conjugate (ADC) development.Learn more about our catalog: en.genomeditech.com/cell-line/Immu…

STEAP1 is back in the spotlight. July 8, the FDA granted orphan drug designation to Adcentrx Therapeutics’ ADC candidate ADRX-0405 — targeting STEAP1 for the treatment of gastric cancer. Learn more about our catalog: en.genomeditech.com/cell-line/TAA/…

Tremfya® (guselkumab) shows promise in Crohn’s disease! Positive Phase III results from GALAXI 2 & 3 published in The Lancet highlight IL-23 targeting as a key advance. #Immunology #Tremfya #Genomeditech Learn more about our catalog: en.genomeditech.com/cell-line/Cyto…

OX40 is a rising star in immunotherapy—powering T cell activation in cancer & autoimmunity. Explore ready-to-use tools to fast-track your OX40 antibody programs.en.genomeditech.com/cell-line/Immu…